News Release

Phase IIa Dosing For Intractable Cancer Pain With Our Platform Drug Ongoing

Date: May 29, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that a further patient is now being dosed at the Calgary site. Our test subjects for our clinical trial on severe pain in palliative cancer patients must undergo stringent inclusion/ exclusion criteria. Frank Shum, CEO stated, "Many more patients are being screened for entry as the sites become familiar with our criteria and patients become aware of our clinical testing program and the uniqueness of our product."

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.